Lash Serum Side Effects: What They Are, Why They Happen & How to Avoid Them
Key takeaways
What You Need to Know About Lash Serum Side Effects
All serious, permanent side effects are associated with prostaglandin-analogue (PGA) ingredients. Peptide-based serums do not share these mechanisms.
PGA compounds stimulate iris melanin production. The FDA confirms this cannot be reversed. Risk is highest for green, blue and hazel eyes.
Prostaglandin-associated periorbitopathy (PAP) creates a sunken, hollow appearance. Ophthalmologists report it in close to 100% of long-term PGA users.
SCCS/1680/25 (2 Feb 2026) confirms ICP, DDDE and MDN "cannot be considered safe" for cosmetic eyelash use. Health Canada banned ICP in 2019.
Triple-peptide formulas (MP-17, BTP-1, AT-3) work on keratin fibre at the follicle — zero documented cases of iris change or fat atrophy.
Persistent redness, pain, visual changes, iris darkening or a hollow appearance around the eyes all warrant immediate review by an eye-care professional.
The EU Scientific Committee on Consumer Safety concluded that isopropyl cloprostenate (ICP), Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) and methylamido-dihydro-noralfaprostal (MDN) "cannot be considered safe" for use in cosmetic products intended to promote eyelash and eyebrow growth. These three ingredients are present in many popular lash serums sold globally.
The Four Serious Side Effects of PGA Lash Serums
Not all lash serums carry the same risk profile. The most clinically significant side effects are exclusive to products containing prostaglandin analogue (PGA) ingredients. Here is what the evidence shows for each documented effect.
Iris Colour Change
PGA compounds stimulate melanin production in iris melanocytes. Light-coloured irises (blue, green, hazel) can permanently darken to brown. The FDA states this "cannot be reversed." Incidence in Latisse trials: approximately 1.5% at 12 months.
Potentially Permanent
Periorbital Fat Atrophy (PAP)
Loss of orbital fat tissue creating a sunken, hollow appearance. A 2013 JAMA Ophthalmology study found measurable periorbital changes in up to 80% of long-term PGA users. Ophthalmologist Dr Stanley Berke reports it "nearly 100% of the time" in chronic prostaglandin users.
May Be Permanent
Eyelid Skin Darkening
Periorbital hyperpigmentation — darkening of the skin around the eyes and on the eyelids — is common with PGA use. France's health agency (ANSES) specifically identified this alongside iris change in their December 2025 cosmetovigilance alert.
Reversible if Caught Early
Eyelid Ptosis (Drooping)
Upper eyelid drooping caused by orbital fat atrophy reducing the support structure of the upper lid. Prolonged PGA use can also cause inferior scleral show — white of the eye becoming visible below the iris at rest.
Linked to Fat Loss
Minor, Transient Side Effects (All Serums)
Both PGA and peptide-based serums can occasionally cause mild, short-lived reactions that typically resolve on their own:
- Localised redness or irritation — usually caused by application too close to the eye's inner corner, or individual sensitivity to a preservative (e.g. phenoxyethanol)
- Mild stinging upon application — more common when the formula contacts the ocular surface rather than the lash line
- Temporary itching — botanical extracts (castor oil, plant peptide carriers) can trigger contact dermatitis in a small proportion of users
- Lash shedding at initiation — some serums push follicles into the growth phase, causing temporary shedding of older lashes first; not a sign of damage
These minor effects are not specific to PGA serums and are transient. They do not indicate the structural or pigmentary changes described above.
Why Prostaglandins Cause These Side Effects
Prostaglandin analogues were originally developed as ophthalmic drugs for glaucoma management (bimatoprost, latanoprost, travoprost). Ophthalmologists observed an unsolicited side effect: lengthened, thickened eyelashes. Cosmetic manufacturers began developing topical cosmetic analogues that could be sold without prescription.
The lash-growth effect is real. So are the risks.
Mechanism: Melanin Stimulation
PGA molecules bind to prostaglandin receptors on melanocytes — pigment-producing cells — in the iris stroma. This triggers increased synthesis of melanin. In eyes already containing high melanin (brown), the change may be imperceptible. In lighter irises, new brown pigment accumulates irreversibly. Once melanocytes are activated this way, they do not de-activate when the product is discontinued.
Mechanism: Orbital Fat Atrophy
Prostaglandin receptors are also present on orbital adipocytes (fat cells). Chronic topical application of PGA compounds promotes lipolysis — breakdown — of periorbital fat, gradually depleting the cushion of tissue that gives eyes their full, youthful appearance. This effect has been confirmed in glaucoma patients on long-term prostaglandin eye drops and has now been reported in cosmetic serum users.
A documented case published by France's national health agency (ANSES, December 2025) describes a woman who, after five months of daily cosmetic serum use containing ICP along the upper lash base, observed marked iris darkening and bilateral periorbital fat loss, creating pronounced dark circles and a hollowed appearance.
Mechanism: Skin Pigmentation
Eyelid skin darkening follows a similar melanocyte-stimulation pathway to iris change, but involves skin melanocytes rather than iris melanocytes. This effect is more commonly reversible if use is discontinued early but can persist with prolonged exposure.
Regulatory Actions: What Authorities Have Said
| Authority | Ingredient(s) Covered | Action | Date |
|---|---|---|---|
| EU SCCS | ICP, DDDE, MDN | Cannot be considered safe in cosmetics (SCCS/1680/25) | 2 Feb 2026 |
| Health Canada | Isopropyl Cloprostenate (ICP) | Banned from cosmetic products | 2019 |
| France / ANSES | ICP (cosmetic serums) | Cosmetovigilance alert — iris change + fat loss confirmed | Dec 2025 |
| US FDA | Bimatoprost 0.03% (Latisse) | Approved as prescription drug; iris change disclosed; not cosmetic | 2008 (ongoing) |
| US FDA | ICP in cosmetics (RapidLash) | Warning letter issued to manufacturer re: drug-like claims | Prior |
Prostaglandins vs Peptides: Side Effect Profile Comparison
The distinction between PGA-based and peptide-based lash serums is not a marketing claim — it is a mechanistic difference at the molecular level.
| Side Effect | PGA Serums (ICP/DDDE/MDN) | Peptide Serums (MP-17/BTP-1/AT-3) |
|---|---|---|
| Iris colour change | Documented — potentially permanent | No documented cases |
| Periorbital fat atrophy | Documented — up to 80% of long-term users | No documented cases |
| Eyelid skin darkening | Common — partially reversible if stopped early | Not reported |
| Eyelid drooping (ptosis) | Associated with fat atrophy | Not reported |
| Localised irritation | Possible — preservatives + active compound | Rare — individual sensitivity to botanical excipients |
| EU regulatory status | SCCS/1680/25 — "cannot be considered safe" | No restriction; peptides are cosmetic-approved actives |
| Mechanism on lash growth | Extends anagen phase via prostaglandin receptor agonism | Stimulates keratin synthesis + follicle conditioning |
How to Check Whether Your Lash Serum Contains Prostaglandins
The challenge is that some brands use obscure INCI names for PGA compounds. Here is the complete list of INCI names to look for — and the brands known to use them:
| INCI Name | Common Name | Known in | Regulatory Flag |
|---|---|---|---|
| Isopropyl Cloprostenate | ICP | GrandeLASH-MD, RapidLash, Babe Lash, NeuLash | HC banned 2019; EU SCCS/1680/25 |
| Isopropyl Phenylhydroxypentene Dihydroxycyclopentylheptanate | ICP (long name) | LiLash Purified Serum | Same compound as ICP — Canadian regs confirm synonymous |
| Dechloro Dihydroxy Difluoro Ethylcloprostenolamide | DDDE | RevitaLash Advanced | EU SCCS/1680/25 |
| Methylamido Dihydro Noralfaprostal | MDN | Various EU/Asian market serums | EU SCCS/1680/25 |
| Bimatoprost 0.03% | Bimatoprost | Latisse (Rx only) | FDA prescription drug — not a cosmetic; iris change disclosed in labelling |
Cross-reference the full INCI list against the names above. Look for clear "prostaglandin-free" or "hormone-free" labelling. Peptide-based actives — Biotinoyl Tripeptide-1 (BTP-1), Myristoyl Pentapeptide-17 (MP-17), Acetyl Tetrapeptide-3 (AT-3), Oligopeptide-2 and similar — do not carry PGA-class risks.
Timeline: When Side Effects Typically Appear
| Timeframe | Possible Side Effects | What to Do |
|---|---|---|
| Days 1–7 | Mild localised irritation, stinging on application, occasional redness (all serum types) | Check application technique — apply only to skin at lash base, not inside the eye. If redness persists beyond 48 hours, stop use. |
| Weeks 2–6 | PGA: subtle eyelid skin darkening may begin; temporary lash shedding phase (all types) | Monitor eyelid skin colour in good light. Shedding of 3–5 lashes during initiation is normal (growth phase transition). |
| Months 2–4 | PGA: periorbital fat changes beginning (often unnoticed initially); continued skin darkening | Compare periorbital area with baseline photos. Any new hollowing or deepening of the lid sulcus should prompt immediate review. |
| Months 5+ | PGA: measurable orbital fat atrophy; possible iris pigment change (documented at 5 months in ANSES case) | Stop PGA serum immediately. Consult ophthalmologist or dermatologist. Early cessation offers the best chance of partial recovery from fat atrophy; iris change may be permanent. |
| Any point | Pain, discharge, blurred vision, visible iris darkening | Stop all serum use immediately. Seek eye-care professional assessment within 48 hours. |
Expert perspective
Cosmetic Chemist's Assessment
"In clinical practice, I see two distinct categories of lash serum problems. The first — transient irritation — is nearly always technique error, and resolves when patients learn to apply a thin line strictly at the lash root, not in the inner corner. The second category is far more serious: the structural and pigmentary changes that develop silently with prostaglandin use. By the time a patient notices the hollowing or the eye colour shift, significant change has already occurred. The only complete protection is avoiding prostaglandin-analogue ingredients entirely. Peptide chemistry offers the same follicle-stimulating benefit without any of these receptor-mediated systemic effects."
When to Stop Immediately and See a Doctor
Stop using any lash serum and consult an eye-care professional (ophthalmologist or optometrist) if you experience any of the following:
- Persistent redness — irritation that does not resolve within 48 hours after stopping application
- Pain or burning sensation — in or around the eye or on the eyelid
- Visible swelling of the eyelid or surrounding tissue
- Any visual changes — blurring, altered contrast, light sensitivity or visual distortion
- Discharge from the eye — potential sign of infection or allergic reaction
- Iris colour change — any perceived darkening of a previously light-coloured iris
- Hollowing or sunken appearance developing around the eyes, new depth in the upper lid sulcus, or increased dark circles you cannot attribute to lifestyle
These symptoms warrant professional evaluation regardless of which serum you are using or how long you have been using it.
Toplash Eyelash Enhancement Serum
Triple-peptide formula (MP-17, BTP-1, AT-3) · PGA-free · Paraben-free · Ophthalmologist-tested · EU SCCS compliant
+52.3% lash length · +31.9% volume at 8 weeks (independent clinical trial) · First results by Day 21
$49.90 / 3 mL ($16.63/mL)
Shop Toplash — No PGAsFrequently asked questions
Lash Serum Side Effects — FAQ
What are the most serious side effects of lash serums?
The most serious side effects are associated with prostaglandin-analogue ingredients (ICP, DDDE, MDN). These include permanent iris colour darkening (especially in light-coloured eyes), periorbital fat atrophy causing a sunken or hollow appearance, eyelid skin darkening, and upper eyelid drooping (ptosis). These effects are well-documented and some — particularly iris darkening — are irreversible. Peptide-based serums do not share these mechanisms and have no documented cases of these effects.
Can a lash serum permanently change your eye colour?
Yes — but only if the serum contains a prostaglandin analogue such as bimatoprost, isopropyl cloprostenate (ICP) or similar ingredients. These compounds stimulate melanin production in iris melanocytes, causing irreversible darkening of light-coloured irises (blue, green, hazel). The FDA states explicitly that iris darkening from bimatoprost "cannot be reversed." Peptide-based lash serums work through different pathways and have no mechanism to affect iris pigmentation.
What is periorbital fat atrophy and is it reversible?
Periorbital fat atrophy (also called prostaglandin-associated periorbitopathy, or PAP) is a hollowing or sunken appearance around the eyes caused by loss of orbital fat tissue. It is associated with prolonged use of prostaglandin-analogue ingredients. If caught early and use is discontinued, some recovery is possible; however, prolonged use can lead to permanent changes. Ophthalmologist Dr Stanley Berke has noted PAP can be observed "nearly 100% of the time" in patients on prostaglandin eye drops.
What did the EU ruling in 2026 say about lash serum ingredients?
On 2 February 2026, the EU Scientific Committee on Consumer Safety published Opinion SCCS/1680/25, concluding that three prostaglandin-analogue ingredients — isopropyl cloprostenate (ICP), Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) and methylamido-dihydro-noralfaprostal (MDN) — "cannot be considered safe" for use in cosmetic products intended to promote eyelash and eyebrow growth. This followed Health Canada's ban on ICP from cosmetics in 2019 and France's ANSES cosmetovigilance alert in December 2025.
What side effects can peptide-based lash serums cause?
Peptide-based lash serums can occasionally cause mild, localised irritation, redness or stinging — typically due to individual sensitivity to a preservative or botanical extract, or from incorrect application technique (applying too close to the eye's inner corner). These effects are transient and resolve quickly on stopping use. There are no documented cases of iris colour change, periorbital fat loss or permanent structural changes from peptide-based formulas.
How can I tell if my lash serum contains a prostaglandin analogue?
Check the ingredient list (INCI) for: isopropyl cloprostenate, dechloro dihydroxy difluoro ethylcloprostenolamide, methylamido-dihydro-noralfaprostal, bimatoprost, or ethyl tafluprostamide. Trade-name substitutions exist: LiLash lists "isopropyl phenylhydroxypentene dihydroxycyclopentylheptanate", which Canadian regulators confirm is the same compound as ICP. Brands containing prostaglandins include GrandeLASH-MD (ICP), RevitaLash Advanced (DDDE), RapidLash (ICP), Babe Lash Essential (ICP), LiLash (ICP), NeuLash (ICP) and Latisse (bimatoprost, prescription).
When should I stop using a lash serum and see a doctor?
Stop using any lash serum and consult an eye-care professional if you experience: persistent redness or irritation that does not resolve within 48 hours, pain or a burning sensation in or around the eye, swelling of the eyelid, any visual changes or blurring, noticeable iris colour change, discharge or signs of infection, or a hollowing or sunken appearance developing around the eye. These symptoms warrant professional evaluation regardless of which serum you are using.
Sources
References & Further Reading
- EU SCCS — Opinion SCCS/1680/25, 2 February 2026: Safety of prostaglandin analogues ICP, DDDE and MDN in cosmetic eyelash products. health.ec.europa.eu
- Health Canada — Isopropyl Cloprostenate: Banned from Cosmetics, 2019. canada.ca
- France ANSES — Cosmetovigilance Alert: Eyelash growth serums may change your eye colour. December 2025. anses.fr
- American Academy of Ophthalmology (AAO) — Latisse and prostaglandin side effects. aao.org
- Peplinski LS, Bhagat N et al. — "Prostaglandin-associated periorbitopathy (PAP) in glaucoma patients." JAMA Ophthalmology 2013.
- FDA — Bimatoprost (Latisse) Prescribing Information and Risk Summary. fda.gov
- Skintypesolutions.com — Prostaglandin Analogues for Lashes: Are They Safe? skintypesolutions.com
- Premium Beauty News — French health agency warns of risks linked to certain eyelash growth products. December 2025. premiumbeautynews.com
- Typology — Prostaglandin derivatives: what does the regulation say? typology.com
- Toplash Clinical Data — Independent clinical trial: +52.3% lash length, +31.9% volume at 8 weeks. Available at toplash.com/pages/clinical-study
- We Love Eyes — Prostaglandin Lash Serum Side Effects Explained. weloveeyes.com
- Plume Science — Lash Serum Safety: Which Ingredients Cause Side Effects? plumescience.com
Published: Jun 20, 2026
